Erasca Raises $259 Million, ERAS-0015 Yields Early Partial Responses
Erasca's pan-RAS molecular glue ERAS-0015 demonstrated ongoing partial responses at an 8 mg QD dose with no dose-limiting toxicities and favorable PK, and ERAS-0015 Phase 1 monotherapy data is expected in H1 2026 with ERAS-4001 results in H2 2026. A $259 million January upsized offering raises pro forma cash to $434 million, funding operations into H2 2028.
1. Clinical Progress
Erasca's pan-RAS molecular glue ERAS-0015 demonstrated ongoing partial responses at an 8 mg QD dose across multiple RAS-mutant tumor types with no dose-limiting toxicities and favorable pharmacokinetic profile. The company anticipates full Phase 1 monotherapy data for ERAS-0015 in the first half of 2026 and initial ERAS-4001 pan-KRAS inhibitor data in the second half of 2026.
2. Financing and Cash Position
In January, Erasca completed an upsized public offering that raised approximately $259 million in gross proceeds, boosting its pro forma cash, cash equivalents, and marketable securities to $434 million. This capital infusion is expected to fund clinical programs and operations into the second half of 2028.
3. Licensing Expansion and Patent Protection
Erasca expanded its licensing agreement with Joyo Pharmatech to secure worldwide rights for ERAS-0015, including China, Hong Kong, and Macau. The U.S. Patent and Trademark Office issued composition patents for ERAS-0015 until September 2043 and ERAS-4001 until June 2043, subject to term adjustments.